Ajax Therapeutics

About Ajax Therapeutics

Ajax Therapeutics focuses on developing targeted therapies for hematologic cancers, with a particular emphasis on myeloproliferative neoplasms (MPNs). The company uses state-of-the-art computational chemistry and structural biology to discover and optimize therapies that are highly selective for JAK2 and other related targets, aiming to overcome disease persistence and reduce mutant allele burden. Its clinical program centers on a next-generation Type II JAK2 inhibitor, AJ1-11095, in early-phase trials for myelofibrosis, and it highlights a commitment to precision targeting to address significant unmet medical needs in blood cancers. Headquartered in the United States, Ajax communicates an R&D focus on next-generation inhibition strategies and preclinical/clinical data dissemination.